Hi, do you all plan on remaining an LLC for tax purposes post note-conversion, and do you anticipate becoming profitable any time soon?

Hi Lucas, We plan on converting to a C-Corp at the end of this year. Our business model is to create value while de-risking during clinical and regulatory development and then license or sell our assets to a commercialization partner. These licenses and/or sales could be very profitable for the company and 1 or 2 could occur within the next 12-18 months. Jim

Hello, thank you for offering this opportunity. Do you plan to set the company up for an acquisition or have distributions once the company is in a good place financially? I appreciate any context you can provide around the future expectations of the company.

HI David, Our goal is to sell or license all of our assets within 5 years and distribute the proceeds. When an individual asset is sold or licensed, and the proceeds are greater then the operating expenses needed to achieve an appreciable valuation inflection point, we would have a distribution of the excess cash. Our Q4-Executive Summary can be found at the bottom of the campaign page. For reference there are links to market analysis and valuation for 2 of our assets; SJP-001 (Alcohol Hangov...

will investors get dividends

HI Adrian, Our goal is to sell or license all of our assets within 5 years and distribute the proceeds. When an individual asset is sold or licensed, and the proceeds are greater then the operating expenses needed to achieve an appreciable valuation inflection point, we would have a distribution of the excess cash. Jim

Hello. It appears to me that your hangover cure is a combination of naproxen, a common over the counter NSAID (e.g. Aleve) and Fexofenadine, a common over the counter antacid (e.g. Allegra). Do you have any propriety IP given that these are readily available to the public?

Hi Cedric, Yes, you can see our entire patent portfolio for our hangover cure in our Q4-Executive Summary at the bottom of the WeFunder campaign page. We have been granted Use & Formulation patents for the US, Japan, Australia, and South Africa. We have just received the Intent to grant for Europe and are still prosecuting in 6 other countries. Jim

Hi, I really like your target group, but how do you explain the fact that one can buy two separate medications (one NSAID + one antihistamine), readily available, and take them at once? Is it based on the fact that your medication will be branded for these specific cases?

Hi Neofytos, Yes, our product will be branded for its specific use. By obtaining FDA approval, we can make marketing claims, unlike supplements in this category. We will be performing a clinical trial to determine dose optimization of each component within the product. The finished product may not be readily available as individual components. Our product would offer convenience to the consumer, FDA approval, and proper labeling for use. Jim

Sen-Jam Pharmaceutical

Decoding the Biology of Resilience to Generate the Next Generation of Longevity Therapeutics

Pitch Video

Investor Panel

sen-jam.com

Huntington, New York

Technology Notable Angel Female Founder B2B Healthcare

Investor Panel

Play Video

What Investors Say

LEAD INVESTOR

Sen-Jam Pharmaceutical

Quick facts

Team profiles

Featured investor profiles

Never miss an update

Investor Panel

What Investors Say